ABSTRACT:The pharmacokinetics and metabolism of 1-(4-((4-phenyl-5-trifluoromethyl-2-thienyl)methoxy)benzyl)azetidine-3-carboxylic acid (MRL-A), a selective agonist for the sphingosine-1-phosphate 1 (S1P 1 ) receptor, were investigated in rats and dogs. In both species, more than 50% of the dose was excreted in bile. Specific to the rat, and observed in bile, were a taurine conjugate of MRL-A and a glucuronide conjugate of an azetidine lactam metabolite. In dogs, a smaller portion of the dose (54% of administered dose) was excreted intact in bile, and the major metabolites detected were an azetidine N-oxide of MRL-A and an acylglucuronide of an N-dealkylation product. This latter metabolite was also observed in rat bile. Stereoselective formation of the N-oxide isomer was observed in dogs, whereas the rat produced comparable amounts of both isomers. The formation of a unique glutathione adduct was observed in rat bile, which was proposed to occur via N-dealkylation, followed by reduction of the putative aldehyde product to form the alcohol, and dehydration of the alcohol to generate a reactive quinone methide intermediate. Incubation of a synthetic standard of this alcohol in rat microsomes fortified with reduced glutathione or rat hepatocytes resulted in formation of this unique glutathione adduct.Sphingosine-1-phosphate (S1P) is a lysophospholipid with cell signaling properties that mediates its action through a family of G-protein-coupled receptors to elicit its effects on cell function (Fukushima et al., 2001). These S1P receptors are expressed in endothelial, lymphoid, pulmonary, cardiovascular, nervous, and renal tissues. Activation of S1P receptors is implicated in angiogenesis, cardiovascular development, and immune system function (Osborne and Stainier, 2003;Spiegel and Milstien, 2003). Analogs of S1P, such as FTY 720, have been shown to be agonists of S1P receptors and cause immunosuppression by promoting the sequestration of circulating lymphocytes into secondary lymphoid organs, which results in peripheral lymphopenia and prevents T lymphocyte infiltration of transplanted or antigen-bearing nonlymphoid tissues (Mandala et al., 2002;Xie et al., 2003). 1-(4-((4-Phenyl-5-trifluoromethyl-2-thienyl)methoxy)benzyl)-azetidine-3-carboxylic acid (MRL-A) is a selective agonist for the S1P 1 receptor that is expressed on endothelial and lymphoid tissues.Potential clinical targets for an S1P 1 agonist are psoriasis, rheumatoid arthritis, renal transplantation, and multiple sclerosis.Before clinical testing, a new class of therapeutic agent has to be characterized in terms of preclinical metabolism and excretion studies. These disposition investigations are conducted along with safety studies in two animal species (Lin and Lu, 1997). Rat as a rodent and dog or monkey as a nonrodent species are commonly used for preclinical toxicology and drug metabolism studies. Although all mammals are similar from an evolutionary standpoint because of their common origin, differences in metabolism of drugs are noted among variou...